Alpha Natural Resources (NYSE:ANR)‘s stock had its “market perform” rating reiterated by equities research analysts at FBR Capital Markets in a research note issued to investors on Tuesday, Stock Ratings News reports. They currently have a $5.00 target price on the stock, down from their previous target price of $6.00. FBR Capital Markets’ price target would indicate a potential upside of 15.21% from the stock’s previous close. Alpha Natural Resources, Inc. (NYSE:ANR) shares after opening at $4.49 moved to $4.77 on last trade day and at the end of the day closed at $4.56. Company price to sales ratio in past twelve months was calculated as 0.20 and price to cash ratio as 1.05. Alpha Natural Resources, Inc. (NYSE:ANR) showed a positive weekly performance of 7.04%.
Magnum Hunter Resources Corporation (NYSE:MHR) announced that it has declared a monthly cash dividend on the Company’s 10.25% Series C Cumulative Perpetual Preferred Stock (“Series C Preferred Stock”), a monthly cash dividend on the Company’s 8.0% Series D Cumulative Preferred Stock (“Series D Preferred Stock”) and a monthly cash dividend on the Company’s 8.0% Series E Cumulative Convertible Preferred Stock (“Series E Preferred Stock”). The outstanding shares of Series E Preferred Stock are represented by depositary shares (the “Depositary Shares”), each representing a 1/1,000th interest of a share of Series E Preferred Stock.Magnum Hunter Resources Corp (NYSE:MHR) shares ended the day on $8.50. MHR return on equity ratio is recorded as -102.30% and its return on assets is -17.20%. Magnum Hunter Resources Corp (NYSE:MHR) yearly performance is 110.40%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) expects its net revenue for the year to come in at $35 million most of which will be impacted by Belviq sales. Revenue will be comprised of $17 million from other items with the remaining $18 million expected to come from the sales of Belviq. Arena receives 31.5% of Belviq sales with the remaining going to its partners. This essentially means that total sales for the year will need to come in at $57 million for the company to attain such high margins.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares moved down -3.12% in last trading session and was closed at $6.22, while trading in range of $6.11-$6.59. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date performance is 6.32%.
Ariad Pharmaceuticals (NASDAQ:ARIA) Insider Timothy P. Clackson sold 6,500 shares of Ariad Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $8.21, for a total value of $53,365.00. Following the transaction, the insider now directly owns 403,028 shares in the company, valued at approximately $3,308,860. The sale was disclosed in a filing with the SEC, which can be accessed through this link.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -5.01%. On last trading day company shares ended up $7.58. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average is -6.34%. Analysts mean target price for the company is $8.84.